Dermata Therapeutics, Inc. (DRMA) — SEC Filings
Dermata Therapeutics, Inc. (DRMA) — 2 SEC filings. Latest: 10-K (Mar 26, 2026). Includes 1 10-K, 1 8-K.
View Dermata Therapeutics, Inc. on SEC EDGAR
Overview
Dermata Therapeutics, Inc. (DRMA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 26, 2026: Dermata Therapeutics, Inc. (DRMA) reported a significant strategic pivot in September 2025, shifting from developing prescription (Rx) acne treatments to direct-to-consumer (DTC) and business-to-business (B2B) skincare products. This change followed statistically significant Phase 3 STAR-1 clinical
Sentiment Summary
Across 2 filings, the sentiment breakdown is: 1 neutral, 1 mixed. The dominant filing sentiment for Dermata Therapeutics, Inc. is neutral.
Filing Type Overview
Dermata Therapeutics, Inc. (DRMA) has filed 1 10-K, 1 8-K with the SEC between Mar 2026.
Recent SEC Filings (2)
| Date | Form | Description | Risk |
|---|---|---|---|
| Mar 26, 2026 | 10-K | Dermata Pivots to DTC Skincare After Rx Acne Trial Success | high |
| Mar 26, 2026 | 8-K | 8-K Filing |
Risk Profile
Risk Assessment: Of DRMA's 1 recent filings, 1 were flagged as high-risk, 0 as medium-risk, and 0 as low-risk. The overall risk profile suggests elevated risk that warrants close monitoring.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$15.5 million |
| EPS | -$3.85 |
| Debt-to-Equity | 0.00 |
| Cash Position | $10.3 million |
| Operating Margin | N/A |
| Total Assets | $17.1 million |
| Total Debt | $0 |
Key Executives
- Trump presidential administration
Industry Context
The skincare industry is characterized by intense competition, rapid innovation, and a growing consumer demand for natural, science-backed products. The shift towards DTC and OTC channels reflects a broader trend of disintermediation and direct consumer engagement. Dermata aims to leverage its unique Bioneedle technology to carve out a niche in this crowded market, particularly in the large acne treatment segment where consumers often prefer OTC options.
Top Tags
Biotechnology (1) · Skincare (1) · Direct-to-Consumer (1) · OTC Products (1) · Strategic Pivot (1) · Clinical Trials (1) · Pharmaceuticals (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Aggregate market value of non-affiliate common equity | $3.1 million | As of June 30, 2025, indicating a small market capitalization. |
| Outstanding shares of common stock | 4,022,143 | As of March 25, 2026. |
| Fiscal Year Ended | 2025 | The period covered by this 10-K filing. |
| Date of Phase 3 STAR-1 trial results | March 2025 | XYNGARI achieved statistically significant results. |
| Date of strategic pivot decision | September 2025 | Shifted from Rx to DTC/B2B skincare. |
| Planned launch of first cosmetic product | Mid-2026 | Marks the beginning of the new DTC strategy. |
| U.S. patients with acne | 50 million | Highlights the large target market for OTC acne products. |
| Acne patients trying OTC products first | 70% | Supports the rationale for the strategic pivot to OTC. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Dermata Therapeutics, Inc. (DRMA)?
Dermata Therapeutics, Inc. has 2 recent SEC filings from Mar 2026, including 1 10-K, 1 8-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of DRMA filings?
Across 2 filings, the sentiment breakdown is: 1 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Dermata Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Dermata Therapeutics, Inc. (DRMA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Dermata Therapeutics, Inc.?
Key financial highlights from Dermata Therapeutics, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for DRMA?
The investment thesis for DRMA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Dermata Therapeutics, Inc.?
Key executives identified across Dermata Therapeutics, Inc.'s filings include Trump presidential administration.
What are the main risk factors for Dermata Therapeutics, Inc. stock?
Of DRMA's 1 assessed filings, 1 were flagged high-risk, 0 medium-risk, and 0 low-risk.
What are recent predictions and forward guidance from Dermata Therapeutics, Inc.?
Forward guidance and predictions for Dermata Therapeutics, Inc. are extracted from SEC filings as they are enriched.